Literature DB >> 23695498

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

Mike P Wattjes, Lonneke Verhoeff, Willemijn Zentjens, Joep Killestein, Erik T van Munster, Frederik Barkhof, Jeroen J J van Eijk.   

Abstract

Entities:  

Keywords:  Infectious Diseases; MRI; Multiple Sclerosis

Mesh：

Substances：

Year:  2013        PMID： 23695498     DOI： 10.1136/jnnp-2013-304986

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  21 in total

Review 1.  Punctate and curvilinear gadolinium enhancing lesions in the brain: a practical approach.

Authors:  Guillaume Taieb; Alberto Duran-Peña; Nicolas Menjot de Chamfleur; Antoine Moulignier; Eric Thouvenot; Thibaut Allou; Arnaud Lacour; Khe Hoang-Xuan; Jean Pelletier; Pierre Labauge
Journal:  Neuroradiology       Date:  2015-12-23       Impact factor: 2.804

2.  JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Authors:  Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-10       Impact factor: 10.422

3.  Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Authors:  J Hodel; O Outteryck; S Verclytte; V Deramecourt; A Lacour; J-P Pruvo; P Vermersch; X Leclerc
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-27       Impact factor: 3.825

Review 4.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

Review 5.  Brain miliary enhancement.

Authors:  Joseph C J Bot; Linda Mazzai; Rogier E Hagenbeek; Silvia Ingala; Bob van Oosten; Esther Sanchez-Aliaga; Frederik Barkhof
Journal:  Neuroradiology       Date:  2020-01-10       Impact factor: 2.804

Review 6.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

Review 7.  Neurological immune reconstitution inflammatory response: riding the tide of immune recovery.

Authors:  David B Clifford
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

8.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams
Journal:  Ann Neurol       Date:  2014-05-08       Impact factor: 10.422

Review 9.  Immune reconstitution inflammatory syndrome associated with biologic therapy.

Authors:  Malika Gupta; Kashif Jafri; Rebecca Sharim; Susanna Silverman; Sayantani B Sindher; Anupama Shahane; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2015-02       Impact factor: 4.919

Review 10.  Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.

Authors:  S Richard Dunham; Robert Schmidt; David B Clifford
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.